Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.17 AUD Market Closed
Market Cap: 180.1m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Relative Value

ALA doesn't have a meaningful market cap.

The Relative Value of one ALA stock under the Base Case scenario is 0.001 AUD. Compared to the current market price of 0.17 AUD, Arovella Therapeutics Ltd is Overvalued by 99%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALA Relative Value
Base Case
0.001 AUD
Overvaluation 99%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
1
Median 3Y
389.3
Median 5Y
76.5
Industry
2.5
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-5.7
Industry
21.4
Forward
-16.7
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-8.2
Industry
16
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-8.2
Industry
23.3
vs History
14
vs Industry
1
Median 3Y
11.2
Median 5Y
3.5
Industry
2.1
vs History
1
vs Industry
0
Median 3Y
287.6
Median 5Y
58.2
Industry
2.6
vs History
6
vs Industry
0
Median 3Y
188.5
Median 5Y
108.9
Industry
5.1
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-4.9
Industry
13.7
Forward
-13.8
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-4.9
Industry
16.7
Forward
-15.4
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-7.4
Industry
15.1
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-6.6
Industry
18.9
vs History
vs Industry
3
Median 3Y
-38.3
Median 5Y
1.6
Industry
1.9

Multiples Across Competitors

ALA Competitors Multiples
Arovella Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Arovella Therapeutics Ltd
ASX:ALA
178.6m AUD 1 146.7 -20.4 -19 -19
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
726.7B USD 17.8 86.8 46.7 52.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.1 28.8 20 22.9
US
Johnson & Johnson
NYSE:JNJ
345.8B USD 3.9 23.6 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
252.5B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
205.3B CHF 3.5 17.9 10 11.9
UK
AstraZeneca PLC
LSE:AZN
166.1B GBP 4.2 32.3 169.7 254.3
CH
Novartis AG
SIX:NOVN
174B CHF 3.9 10.9 9.5 13.2
US
Pfizer Inc
NYSE:PFE
152.4B USD 2.5 35.8 10.6 16.1
P/E Multiple
Earnings Growth PEG
AU
Arovella Therapeutics Ltd
ASX:ALA
Average P/E: 32.1
Negative Multiple: -20.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
86.8
76%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
28.8
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.6
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
17.9
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.3
40%
0.8
CH
Novartis AG
SIX:NOVN
10.9
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average EV/EBITDA: 459.4
Negative Multiple: -19
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.7
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.4
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10
7%
1.4
UK
AstraZeneca PLC
LSE:AZN
169.7
18%
9.4
CH
Novartis AG
SIX:NOVN
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average EV/EBIT: 2 011.1
Negative Multiple: -19
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.1
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
22%
1
US
Johnson & Johnson
NYSE:JNJ
14.8
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
11.9
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
254.3
32%
7.9
CH
Novartis AG
SIX:NOVN
13.2
17%
0.8
US
Pfizer Inc
NYSE:PFE
16.1
19%
0.8